SE9303612D0 - New use - Google Patents
New useInfo
- Publication number
- SE9303612D0 SE9303612D0 SE9303612A SE9303612A SE9303612D0 SE 9303612 D0 SE9303612 D0 SE 9303612D0 SE 9303612 A SE9303612 A SE 9303612A SE 9303612 A SE9303612 A SE 9303612A SE 9303612 D0 SE9303612 D0 SE 9303612D0
- Authority
- SE
- Sweden
- Prior art keywords
- medicament
- pla2
- heparin
- phospholipases
- low
- Prior art date
Links
Abstract
The present invention relates to the use of low anticoagulant heparin (LA-heparin), low molecular weight-low anticoagulant heparin (LMW-LA-Heparin) or low anticoagulant heparan sulphate for the manufacture of a medicament regulating phospholipases A2 (PLA2). The medicament can be used against myotoxic phospholipases A2 (PLA2) and against bites from snakes or insects. The medicament also inhibits cellular PLA2 in human leukocytes and can be used for treating tissue damages caused by PLA2 and function as an anti-inflammatory medicament. The medicament can be adapted for injectable, topical or oral administration.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9303612A SE9303612D0 (en) | 1993-11-02 | 1993-11-02 | New use |
AU81195/94A AU8119594A (en) | 1993-11-02 | 1994-11-02 | Use of low anticoagulant heparinderivatives |
PCT/SE1994/001030 WO1995012403A1 (en) | 1993-11-02 | 1994-11-02 | Use of low anticoagulant heparinderivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9303612A SE9303612D0 (en) | 1993-11-02 | 1993-11-02 | New use |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9303612D0 true SE9303612D0 (en) | 1993-11-02 |
Family
ID=20391615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9303612A SE9303612D0 (en) | 1993-11-02 | 1993-11-02 | New use |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU8119594A (en) |
SE (1) | SE9303612D0 (en) |
WO (1) | WO1995012403A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744457A (en) * | 1995-03-31 | 1998-04-28 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
US5763427A (en) * | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
US6001820A (en) * | 1995-03-31 | 1999-12-14 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
US5980865A (en) * | 1995-08-18 | 1999-11-09 | Baker Norton Pharmaceuticals, Inc. | Method for treating late phase allergic reactions and inflammatory diseases |
US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
BR112020019213A2 (en) | 2018-03-27 | 2021-01-05 | Brian Lohse | MYOTOXIN NEUTRALIZING PEPTIDES, COMPOSITION THAT UNDERSTANDS THE SAID PEPTIDE AND USE OF THE SAME TO TREAT POISONING |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4879282A (en) * | 1987-03-17 | 1989-11-07 | Saliba Jr Michael J | Medical application for heparin and related molecules |
AU6204594A (en) * | 1993-02-22 | 1994-09-14 | Ulrich-Christoph Von Arnim | Use of heparins for the treatment of inflammatory or immunological diseases |
-
1993
- 1993-11-02 SE SE9303612A patent/SE9303612D0/en unknown
-
1994
- 1994-11-02 AU AU81195/94A patent/AU8119594A/en not_active Abandoned
- 1994-11-02 WO PCT/SE1994/001030 patent/WO1995012403A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1995012403A1 (en) | 1995-05-11 |
AU8119594A (en) | 1995-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69920757D1 (en) | IMMUNE SUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | |
DE69108048T2 (en) | DERIVATIVES OF HYDROXAMIC ACID AND N-HYDROXY URINE, AND THEIR USE. | |
DE69526120T2 (en) | USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC AGENT | |
UA49869C2 (en) | NAPHTHYL-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR TREATMENT (VARIANTS), METHOD FOR INHIBITING HUMAN FACTOR Xa OR IIa | |
DE69710065D1 (en) | Androstene DERIVATIVES | |
ATE282425T1 (en) | METHOD FOR TREATING ENDOTHELIAL INJURIES | |
DE69731610D1 (en) | ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID | |
EA200500804A1 (en) | Topical Anti-infective Compositions | |
SE9602931L (en) | New medical use | |
ATE245452T1 (en) | HYALURONATE LYASE AS A PENETRATION PROMOTER IN TOPICAL AGENTS | |
ATE336997T1 (en) | FULVIC ACID AND ITS USE IN THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | |
EA199900542A1 (en) | COMPOUNDS OF SULPHONIC ACID OR SULPHONYLAMINO-N- (HETEROARALKYL) -ASAGHETHROCYCLOSYME | |
DK1167354T3 (en) | Racemic hypersensitivity A | |
PT888327E (en) | BENZOPIRANE DERIVATIVES THAT MAY HAVE AN ANTAGONISTIC ACTION OF LEUKOTRIENES | |
BR9809678A (en) | Triptolyte derivatives useful in the treatment of autoimmune diseases | |
BRPI0414887A (en) | methods of treatment, prevention, delay of onset or reduction of effects of proinflammatory cytokines on a mammal and treatment, prevention, delay of onset of a condition associated with an effect of proinflammatory cytokines on a mammal, and, pharmaceutical composition | |
SE9303612D0 (en) | New use | |
DE69705110D1 (en) | TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN | |
ATE126061T1 (en) | USE OF LITHIUM FOR THE TREATMENT OR PROPHYLAXIS OF MOLLUSCUM CONTAGIUSUM. | |
BR9809673A (en) | Triptolide derivatives useful in the treatment of autoimmune diseases | |
NO20003510D0 (en) | Fat-Binding Polymers | |
NO990450L (en) | Treatment of mental disorders | |
DE69103773D1 (en) | DERIVATIVES OF HYDROXAMIC ACID INHIBIT THE LIPOXYGENASE. | |
ATE222768T1 (en) | CTLA-8 IN COMBINATION WITH G-CSF OR WITH G-CSF AND IL-6, AND USE OF CTLA-8 TO TREAT INFECTIONS | |
PT1058544E (en) | INHIBITION OF TNF ACTIVITY |